FDA declines to approve re-launch of ADMA Biologics' Bivigam
December 19, 2018 at 18:10 PM EST
The U.S. Food and Drug Administration on Wednesday declined to approve ADMA Biologics Inc's application to re-launch its immune deficiency treatment Bivigam, the company said.